Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

1 Sept 1991

Abstract excerpt

Two forms of activated BCR/ABL proteins, P210 and P185, that differ in BCR-derived sequences, are associated with Philadelphia chromosome-positive leukemias. One of these diseases is chronic myelogenous leukemia, an indolent disease arising in hematopoietic stem cells that is almost always associated with the P210 form of BCR/ABL. Acute lymphocytic leukemia, a more aggressive malignancy, can be associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1875948
DOI: 10.1128/mcb.11.9.4710

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.PMID 1875948Read ↗

The P190, P210, and P230 Forms of the <i>BCR/ABL</i> Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivitySemantic proximity Read ↗

The 5' non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells.Semantic proximity Read ↗

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinaseSemantic proximity Read ↗

BCR/ABL P210 and P190 cause distinct leukemia in transgenic miceSemantic proximity Read ↗

Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.Semantic proximity Read ↗

Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fateSemantic proximity Read ↗

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.Semantic proximity Read ↗

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.Semantic proximity Read ↗

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.Semantic proximity Read ↗

ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.Semantic proximity Read ↗

Induction of Chronic Myelogenous Leukemia in Mice by the P210 <sup> <i>bcr/abl</i> </sup> Gene of the Philadelphia ChromosomeSemantic proximity Read ↗

Bcr-Abl variants: biological and clinical aspects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.